Phase 3 Immunotherapy Clinical Trials
13 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–13 of 13 trials
Recruiting
Phase 3
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University452 enrolled1 locationNCT06964568
Recruiting
Phase 3
18F-FLUC PET/MR in Patients With Brain Mets
Brain MetastasisRadiation TherapyImmunotherapy, Active
University of Wisconsin, Madison30 enrolled1 locationNCT06159335
Recruiting
Phase 3
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Esophagus CancerChemotherapy EffectTargeted Therapy+3 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled5 locationsNCT04821778
Recruiting
Phase 3
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal CancerSurgeryChemotherapy Effect+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled1 locationNCT04821843
Recruiting
Phase 3
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University432 enrolled1 locationNCT06676449
Recruiting
Phase 2Phase 3
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
Gastric CancerImmunotherapyNeoadjuvant Therapies+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06826079
Recruiting
Phase 3
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Neoadjuvant TherapyImmunotherapyLocally Advanced Non-Small Cell Lung Cancer+1 more
Sun Yat-sen University497 enrolled1 locationNCT06734702
Recruiting
Phase 3
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
RadiotherapyImmunotherapyLocally Advanced Rectal Cancer (LARC)+2 more
West China Hospital184 enrolled1 locationNCT07020247
Recruiting
Phase 3
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular CarcinomaImmunotherapyPreoperative
The First Affiliated Hospital with Nanjing Medical University130 enrolled1 locationNCT05613478
Recruiting
Phase 2Phase 3
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Phase 3
Nutrition Impact on Immunotherapy of Cancer
CancerImmunotherapyNutrition Disorders+1 more
Qingdao Central Hospital300 enrolled1 locationNCT06500234
Recruiting
Phase 3
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Urinary Bladder NeoplasmsTreatment OutcomeImmunotherapy, Active+3 more
Fujian Medical University Union Hospital76 enrolled1 locationNCT06441110
Recruiting
Phase 2Phase 3
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Immunotherapy Gastrict Cancer
Fujian Cancer Hospital130 enrolled1 locationNCT05699655